Acute Ischemic Stroke Clinical Trial
Official title:
Prospective, Matched Case Control, Multicenter, Observational Study for the Association of Serum Apolipoprotein B-48 Level and Large arterY Atherosclerotic iSchemic Stroke(ABYSS)
The purpose of this study is to evaluate whether the serum apoB48 level is associated with atherosclerotic ischemic stroke.
Status | Recruiting |
Enrollment | 112 |
Est. completion date | October 2011 |
Est. primary completion date | March 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: Large artery atherosclerotic ischemic stroke group(LAA group) - Age over 20 years - Patients with symptomatic stenosis in the eligible vessels(the middle cerebral artery, anterior cerebral artery, or internal carotid artery) as assessed by MRA or CTA corresponding to the acute ischemic stroke - Patients without the occlusion of corresponding artery by MRA or CTA - The fasting and postprandial serum Apo B-48 level can be assessed within 72 hours after the symptom onset of ischemic stroke Small vessel occlusive ischemic stroke group (SVO group) - Age over 20 years - Patients with acute ischemic stroke of basal ganglia, internal capsule, or corona radiata - Patients without both symptomatic and asymptomatic arterial occlusion or stenosis by MRA or CTA - Patients without a history of systemic atherosclerosis(for example, acute myocardial infarction, angina, peripheral arterial disease, aortic aneurysm) - The fasting and postprandial serum Apo B-48 level can be assessed within 72 hours after the symptom onset of ischemic stroke Exclusion Criteria: both LAA group and SVO group - Patients with cardioembolic ischemic stroke - Patients treated with lipid lowering agents or steroid within the previous 30 dsys - Patients with severe liver disease (AST >100 or ALT >100) at the time of randomization - Patients with endocrine disease except diabetes mellitus at the time of randomization (for example, thyroid disease, adrenal disease) - Patients with severe renal disease (serum creatinine >2.0mg/dl)at the time of randomization - chronic alcoholics or drug user - Patients with infection at the time of randomization - Patients, in the opinion of the investigator, unlikely to comply with the clinical study or unsuitable for the any other disease or reason - Informed consent has not been obtained |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Hallym University Sacred Heart Hospital | Anyang |
Lead Sponsor | Collaborator |
---|---|
Hallym University Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The serum level of fasting apolipoprotein B-48 | 72 hours within stroke onset | No | |
Primary | The serum level of postprandial apolipoprotein B-48 | within 72 hours after stroke onset | No | |
Secondary | The serum level of the postprandial triglyceride | 72 hours within stroke onset | No | |
Secondary | The serum level of fasting total cholesterol | within 72 hours after stroke onset | No | |
Secondary | The serum level of fasting LDL cholesterol | within 72 hours after stroke onset | No | |
Secondary | the level of fasting HDL cholesterol | within 72 hours after stroke onset | No | |
Secondary | the level of fasting triglyceride | within 72 hours after stroke onset | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06113848 -
Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy
|
Phase 3 | |
Completed |
NCT04069546 -
The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency
|
N/A | |
Active, not recruiting |
NCT05700097 -
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
|
Phase 2 | |
Recruiting |
NCT06058130 -
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
|
N/A | |
Recruiting |
NCT04415164 -
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
|
Phase 4 | |
Recruiting |
NCT05363397 -
Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
|
Phase 2 | |
Completed |
NCT05429658 -
Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System
|
N/A | |
Recruiting |
NCT05390580 -
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
|
N/A | |
Enrolling by invitation |
NCT05515393 -
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
|
Phase 2 | |
Active, not recruiting |
NCT05070260 -
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
|
Phase 2/Phase 3 | |
Terminated |
NCT05547412 -
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
|
||
Completed |
NCT03366818 -
New Stent Retriever, VERSI System for AIS
|
N/A | |
Not yet recruiting |
NCT06437431 -
Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05293080 -
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
|
Phase 3 | |
Not yet recruiting |
NCT06040476 -
Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)
|
Phase 2 | |
Completed |
NCT02223273 -
Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)
|
N/A | |
Completed |
NCT02586233 -
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
|
Phase 1/Phase 2 | |
Terminated |
NCT01694381 -
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
|
Early Phase 1 | |
Not yet recruiting |
NCT01594190 -
Physical Activity Immediately After Acute Cerebral Ischemia
|
N/A | |
Completed |
NCT01120301 -
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
|
Phase 3 |